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Abstract
Background: The objective of this ambispective study was to determine outcomes and associated factors for adult
patients with confirmed septic arthritis (SA).
Methods: All adult patients admitted to Amiens University Hospital between November 2010 and December 2013
with confirmed SA were included in the study. Patients with prosthetic joint infections were excluded. A statistical
analysis was performed in order to identify risk factors associated with a poor outcome (including mortality directly
attributable to SA).
Results: A total of 109 patients (mean ± SD age: 60.1 ± 20.1; 74 male/35 females) were diagnosed with SA during
the study period. The most commonly involved sites were the small joints (n = 34, 31.2 %) and the knee (n = 25, 22.
9 %). The most frequent concomitant conditions were cardiovascular disease (n = 45, 41.3 %) and rheumatic disease
(n = 39, 35.8 %). One hundred patients (91.7 %) had a positive microbiological culture test, with Staphylococcus
aureus as the most commonly detected pathogen (n = 59, 54.1 %). Mortality directly attributable to SA was relatively
infrequent (n = 6, 5.6 %) and occurred soon after the onset of SA (median [range]: 24 days [1–42]). Major risk factors
associated with death directly attributable to SA were older age (p = 0.023), high C-reactive protein levels (p = 0.002)
, diabetes mellitus (p = 0.028), rheumatoid arthritis and other inflammatory rheumatic diseases (p = 0.021), confusion
on admission (p = 0.012), bacteraemia (p = 0.015), a low creatinine clearance rate (p = 0.009) and the presence of leg
ulcers/eschars (p = 0.003). The median duration of follow-up (in patients who survived for more than 6 months) was
17 months [6–43]. The proportion of poor functional outcomes was high (31.8 %). Major risk factors associated with
a poor functional outcome were older age (0.049), hip joint involvement (p = 0.003), the presence of leg
ulcers/eschars (p = 0.012), longer time to presentation (0.034) and a low creatinine clearance rate (p = 0.013).
Conclusions: In a university hospital setting, SA is still associated with high morbidity and mortality rates.
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Background
Septic arthritis (SA) is the most serious condition in the
differential diagnosis of an inflamed, swollen joint [1–3].
The diagnosis of SA can be challenging even for doctors
skilled in the management of musculoskeletal disease
[1–3]. The incidence of SA in the USA and Western
Europe has variously been reported as between 2 and 10
per 100,000 patient-years [4–7]. The incidence rises in
specific patient populations; in patients with rheumatoid
arthritis (RA), the annual incidence has been estimated
at 70 cases per 100,000 patient-years [8, 9]. Additional
risk factors for SA include low socioeconomic status,
previous rheumatic disease (e.g. RA, osteoarthritis, crys-
tal arthropathy, and other forms of inflammatory arth-
ritis), previous surgery, diabetes mellitus, leg ulcers,
intravenous drug abuse, alcohol abuse, intra-articular
corticosteroid injection, and (possibly) human immuno-
deficiency virus infection [10–12]. Although all age
groups can be affected, SA mainly usually arises in eld-
erly people and very young children [1–3]. In all age and
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Staphylococcus aureus, followed by other Gram-positive
bacteria (including streptococci) [1–3].
Septic arthritis is a medical emergency, and so delayed
or inadequate treatment can lead to irreversible joint de-
struction and thus substantial morbidity and mortality
[1–3]. In the literature, the reported mortality rate for
SA ranges from 4 to 42 % [13–15], with values as high
as 50 % in polyarticular disease [12]. Morbidity is also
substantial, with persistent joint dysfunction occurring
in up to 30 % of cases [16, 17]. However, very few de-
tailed studies of morbidity, mortality and outcomes in
adult patients with SA have been published in the last
20 years. The primary objective of the present study was
therefore to identify (i) characteristics and outcomes in
adult patients with SA admitted to a university hospital,




This hospital-based, ambispective study was conducted
at Amiens University Hospital (Amiens, France). Epi-
sodes of SA in adult patients (aged ≥16 years) attending
this tertiary hospital over a three-year period (November
2010 to December 2013) were identified. Patients with
prosthetic joint SA or patients with SA following surgi-
cal procedures were excluded from the study, as were
patients with diabetes-related foot infections. The study
was designed in accordance with the ethical standards of
our hospital Ethics Committee (Amiens University Hos-
pital). In view of the study’s design, no written informed
consent to participation was necessary in accordance
with our ethical committee. Indeed, this is an observa-
tional study with usual care.
Case definition
All included patients met one of Newman’s diagnostic
criteria for SA [18]: (A) isolation of an organism from an
affected joint, (B) isolation of an organism from another
site in a patient with a concomitant swollen, inflamed
joint, (C) no organism isolated but clinical features and
turbid joint fluid in patients having undergone prior
antibiotic therapy, and (D) no organism isolated but
histological or radiologic evidence consistent with SA.
Moreover, organisms were isolated and identified with
conventional biochemical assays and tests in Amiens
University Hospital’s microbiology laboratory.
Case identification and data collection
The following methods were applied to identify cases: (i)
consecutive patients with SA diagnosed between No-
vember 2010 and December 2013 were prospectively re-
corded in the diagnosis registry by the attending
clinicians (in the rheumatology, orthopaedics and
infectious disease departments); (ii) patients were identi-
fied retrospectively (in January 2014) by checking the
hospital activity index (HAI) over a three-year period
(November 2010–December 2013).
The patients’ case notes were reviewed from January
2014 onwards by using a structured pro forma report
form. The following items of information were extracted:
age, gender, concomitant conditions, presentation, as-
sessments, investigations, pathogen(s) responsible, treat-
ments and outcomes. If several joints were involved, the
patient was classified as a function of the predominantly
affected joint.
Data on disease outcomes
Data on disease outcomes (collected between January
2014 and July 2014) were obtained from medical records
and, if necessary, from the patients in a phone interview.
When patients could not be contacted or were unable to
answer questions, a family member or general practi-
tioner was interviewed instead. The disease outcomes
questionnaire included a number of closed questions: “Is
the patient still alive?”; “When did death occur?”; “What
was the cause of death?”; “Has your joint function wors-
ened or have you developed any new limitations in joint
function that can be ascribed to SA”.
After a review of the medical records (and a phone
interview, if necessary), the patient outcome was classi-
fied as “poor” in the event of death. We sought to distin-
guish between deaths directly attributable to septic
arthritis and those due to other causes. We considered
that the death was related to SA when this was indicated
in the patient’s case notes. The joint outcome was classi-
fied as “poor” in cases of amputation, arthrodesis, pros-
thetic surgery or severe functional deterioration reported
by the patient. If several joints were involved, the patient
was analyzed as a function of the predominantly affected
joint.
Statistical analysis
Statistical analysis was performed using SAS software
(version 9.3, SAS Institute Inc., Cary NC, USA). Con-
tinuous variables are reported as the median, minimum,
maximum, and missing values; categorical variables are
reported as the frequency and percentage. All tests were
two-sided, with a significance threshold set to p < 0.05.
The various groups were compared using a chi-square
test or Fisher’s exact test for categorical variables, and ei-
ther an analysis of variance (or Student’s t test, for two
groups) or a Kruskal–Wallis test (or a Mann–Whitney
test, for two groups) for continuous variables.
A univariate logistic regression model was used to
screen for risk factors that were predictive of mortality
attributable directly to SA. Likewise, a univariate logistic
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regression model was used to screen for risk factors that
were predictive of a poor functional outcome.
The following potential risk factors were tested: age,
confusion on admission, time to presentation (days),
open and arthroscopic surgery, diabetes mellitus, cardio-
vascular disease, cancer (pre-existing or concomitant),
concomitant or pre-existing skin involvement (eschars
and/or leg ulcers), previous RA and other forms of in-
flammatory arthritis, joint involvement (hip, knee, mul-
tiple or small joints), organism (Staphylococcus aureus),
bacteraemia, C-reactive protein (CRP) and the measured
creatinine clearance rate (evaluated according to the
Modification of Diet in Renal Disease equation).
Results
Identification and selection of cases
A total of 410 adult patients were identified for the study
period (Fig. 1). Twenty-two of the 410 patients were
identified in the prospective diagnosis registry but not in
the retrospective review. Two hundred and ninety-six
patients were excluded following review of their case
notes: 143 had prosthetic joint SA, 27 were aged under
16, 15 had diabetes-related foot infections, 7 had devel-
oped SA following surgery, 7 had osteomyelitis, 7 had
infectious spondylodiscitis, 45 were duplicate cases (pro-
spective records) and 45 had been misdiagnosed with
SA (cases of RA, reactive arthritis, gout, etc.). Hence,
Fig. 1 Study flow chart
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data on the remaining 109 adult patients with confirmed
SA (including 11 with multiple joint involvements) were
analyzed. Most of the patients had been referred to our
rheumatology (n = 51, 47.8 %) and orthopaedics depart-
ments (n = 37, 33.9 %), with fewer referrals to our infec-
tious disease (n = 20, 18.3 %) and geriatric medicine
departments (n = 1, <1 %) (Table 1).
Demographics, affected joints and pathogens
As mentioned above, 109 patients (with a total of 130
infected joints) were included (median [range] age: 62
[16–96]; n = 74 males, 67.9 %; median [range] BMI: 25
[14.5–48] kg/m2) (Table 1). In terms of the Newman cri-
teria, 91 of the 109 patients (83.5 %) were in group A,
with 9 in group B, 5 in group C and 4 in group D. Joint
involvement is summarized in Table 2. The most fre-
quently involved sited were the small joints (fingers and
toes) (n = 34, 31.2 %), followed by the knee (n = 25,
22.9 %), the shoulder (n = 16, 14.7 %) and the hip (n =
12, 11.0 %). Patients with small joint involvement dif-
fered significantly in terms of age (52.0 ± 22.6 vs. 63.3 ±
18.4, p < 0.01) and most of them were referred to the
orthopaedic department (n = 28, 82.3 %) (Table 1).
The data on bacterial isolates are summarized in
Table 3. Staphylococcus aureus was the most commonly
isolated bacteria (n = 54). Nine of the latter cases were
due to methicillin-resistant strains. Streptococci and
Pasteurella were involved in 11 and 7 episodes of SA,
respectively.
Concomitant conditions
The most frequent concomitant conditions in our
study population are listed in Table 4: cardiovascular
disease (n = 45, 41.3 %), including heart disease (n =
37, 33.9 %) and peripheral arterial disease (n = 19,
17.4 %); pre-existing rheumatic disease (n = 39,
35.8 %), including osteoarthritis (n = 24, 22.0 %),
gout/chondrocalcinosis (n = 15, 13.8 %), RA and
other inflammatory rheumatic diseases (n = 7, 6.4 %).
Furthermore, 6 of the 7 latter patients were taking
immunosuppressants. Diabetes mellitus and cancer
were noted in 26 (23.9 %) and 22 (20.2 %) patients,
respectively. Concomitant or pre-existing skin in-
volvement (eschars and/or leg ulcers) was found in
16 (14.7 %) patients. Patients with small joint in-
volvement differed significantly from patients with
large joint involvement in terms of cardiovascular
disease (17.6 % vs. 52.0 %, respectively; p < 0.01) and
diabetes (11.8 % vs. 29.3 %, p = 0.04) (Table 1).
Table 1 Characteristics of the study participants







Age, years 109 62 [16–96] 52.5 [16–89] 65 [17–96] <0.01
Male gender, n (%) 109 74 (67.9) 19 (55.9) 55 (73.3) 0.07
Body mass index (kg/m2) 80 25 [14.5–48] 24.1 [17–40.4] 26.05 [14.5–48] 0.25
Creatinine clearance (ml/min) 105 80 [5–150] 84 [13–150] 78 [5–150] 0.35
C-reactive protein (mg/l) 102 120 [3–640] 23 [3–230] 166 [3–640] <0.01
Length of hospital stay (days) 109 16 [2–216] 6 [2–56] 21 [2–216] <0.01
Duration of oral therapy (days) 102 52.5 [3–112] 42 [3–84] 84 [10–112] <0.01
Department, n (%) 109
-Rheumatology 51 (47.8) 5 (14.7) 46 (61.4)
-Orthopaedics 37 (33.9) 28 (82.3) 9 (12.0)
-Infectious Dis. 20 (18.3) 1 (3.0) 19 (25.3)
-Geriatric Med. 1 (<1) 0 (<1) 1 (1.3) <0.01
Staphylococcus aureus, n (%) 109 59 (59.0) 16 (51.6) 43 (62.3) 0.31
Diabetes, n (%) 109 26 (23.8) 4 (11.8) 22 (29.3) 0.04
Cardiovascular disease, n (%) 109 45 (41.3) 6 (17.6) 39 (52.0) <0.01
Cancer, n (%) 109 22 (20.2) 4 (11.8) 18 (24.0) 0.14
Surgery, n (%) 109 60 (55.0) 26 (75.5) 34 (45.3) <0.01
All-cause death, n (%) 107 19 (17.8) 2 (6.2) 17 (22.7) 0.04
Death directly attributable to SA, n (%) 107 6 (5.6) 0 (<1) 6 (8.0) 0.10
Poor functional outcome, n (%) 88 28 (31.8) 7 (23.3) 21 (36.2) 0.22
Data are reported as the median [range]. Statistically significant results are indicated in bold type
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Diagnosis and presentation
The median [range] time to presentation was 7 [1–120]
days. A history of fever was recorded in 44 % of cases,
with rigor in 27 % and sweating in only 16 %. Fever
(>37.5 °C) and confusion on admission were respectively
detected in only about 46 % (48 of 104) and 12 % (13 of
109) of cases.
The CRP level was elevated (>3.2 mg/l) in 96.1 % of
the 102 tested patients (median [range]: 120 [3–640]
mg/l). Moreover, CRP levels were lower in patients with
small joint involvement than in those with large joint in-
volvement (23 [3–230] mg/l vs. 166 [3–640] mg/l, re-
spectively, p < 0.01). Serum procalcitonin levels were
rarely determined (in fewer than 30 % of patients). The
median creatinine clearance rate was 80 [5–150] ml/min
in the 105 tested patients, with variously <15 ml/min (n
= 4), 15–29 ml/min (n = 7), 30–59 ml/min (n = 17), 60–
89 ml/min (n = 34) and ≥90 ml/min (n = 43) (Table 1).
The total white cell count was elevated (>10,000) in only
50 % of the 105 tested patients. Anaemia (haemoglobin
<12 g/dl) was observed in 50 % of the 105 tested
patients.
One hundred and nine patients had at least one sam-
ple sent for microbiological testing. One hundred of
these (91.7 %) had a positive culture. Specifically, organ-
isms were identified in the synovial fluid in 86 (84.3 %)
of the 102 patients that had synovial fluid analysed. Of
the 79 patients who had blood cultures, 31 (39.2 %) were
positive. In 11 of these, blood cultures were the only
positive result. Forty three patients had synovial fluid
sent in blood culture media and 30 (69.8 %) were posi-
tive. In just one case, this was the only positive micro-
biological test. Lastly, 16S rRNA gene sequencing was
the only positive microbiological test in 2 patients (re-
vealing Streptococcus agalactiae and Streptobacillus
moniliformis, respectively).
Transoesophageal echocardiography and transthoracic
echocardiography were performed in 17 and 48 cases,
respectively, and enabled the detection of four cases of
infectious endocarditis.
Treatment
All patients were hospitalized. The median length of
hospital stay (LOS) was 16 [2–216] days. The dur-
ation of treatment was very variable, with median du-
rations of intravenous therapy and oral therapy of 8
[2–31] days and 52.5 [3–112] days, respectively. It is
noteworthy that initial intravenous therapy was
administered in 95 of the 109 cases (87.1 %). Interest-
ingly, patients with small joint involvement had a sig-
nificantly shorter LOS (6 [2–56], vs. 21 [2–216] days
for patients with large joint involvement; p < 0.01) and
duration of oral therapy (42 [3–84] vs. 84 [10–112],
respectively; p < 0.01) (Table 1). Various antibiotic
combinations were used in initial intravenous treat-
ment, with the most common being aminoglycoside
and oxacillin (n = 34), aminoglycoside and vancomycin
(n = 10), aminoglycoside and amoxicillin (n = 9) and
aminoglycoside and amoxicillin/clavulanic acid (n = 8).
In terms of oral therapy, the most commonly used
combinations were rifampicin and fluoroquinolones
(n = 35), followed by dalacin and fluoroquinolones (n
= 15). Sixty of the 109 patients (55 %) required surgi-
cal lavage (arthroscopic washout in 8 cases and
arthrotomy/washout in 52 cases).
Disease outcomes
The disease outcomes data for two of the 109 patients
(<2 %) were incomplete because the patients could not
be contacted. Both of these cases (a 17-year-old male
Table 2 Joint sites involved with SA (109 adult patients with
confirmed SA (including 11 with multiple joint involvements








34 31.2 36 27.7
Knee 25 22.9 31 23.9
Shoulder (glenohumeral or
acromioclavicular)
16 14.7 20 15.4
Hip 12 11.0 16 12.3
Ankle or subtalar 9 8.2 14 10.8
Sacroiliac 5 4.6 5 3.8
Symphisis pubis 3 2.7 3 2.3
Wrist 2 1.9 2 1.5
Elbow 2 1.9 2 1.5
Sternoclavicular 1 0.9 1 0.8
Table 3 Organisms identified as causes of SA




- β-haemolytic streptococci 7
- S. pneumoniae 2
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and a 60-year-old female) involved finger joint infection
with S. aureus. The median duration of follow-up (in pa-
tients surviving for more than 6 months) was 17 months
[6–43].
Nineteen of the patients with SA (17.8 %) died; 6 of
these mortalities were considered to be directly attribut-
able to SA (5.6 %) and occurred soon after the onset of
the SA (median: 24 days [1–42]). The remaining 13 pa-
tients died from causes other than SA: cardiovascular
disease (n = 6), bed confinement (n = 3), kidney failure
(n = 1), macrophage activation syndrome (n = 1), suicide
(n = 1) and cancer (n = 1).
Our univariate analysis suggested that older age (odds
ratio (OR) [95 % confidence interval] per year: 1.09
[1.02–1.19]; p = 0.023), CRP (OR per unit: 1.01 [1.006–
1.02]; p = 0.002), bacteraemia (OR 15.20 [2.31–298.70];
p = 0.015), skin involvement (OR: 14.83 [2.62–115.71]; p
= 0.003), RA or other inflammatory rheumatic diseases
(OR 9.60 [1.14–64.04]; p = 0.021), diabetes mellitus (OR
7.18 [1.31–54.31]; p = 0.028), confusion on admission
(OR 9.10 [1.51–55.39]; p = 0.012) and a low creatinine
clearance rate (OR per unit: 0.96 [0.92–0.99]; p = 0.009)
were predictive of mortality directly attributable to SA
(Table 5).
The morbidity was also considerable, since a poor
functional outcome was observed in 28 of the 88 eligible
patients (31.8 %): eleven patients had severe functional
deterioration; amputation was necessary in 8 patients,
osteosynthesis in 4 patients and joint replacement in 5
patients. In terms of the hip joint, a poor functional
outcome was found in 8 of the 10 eligible patients with
severe functional deterioration in 5 patients and joint re-
placement in 3 patients. Data on univariate risk factors
for poor functional outcome are summarized in Table 6.
The analysis suggested that older age (OR per year: 1.02
[1.001–1.05]; p = 0.049), hip joint involvement (OR:
11.60 [2.65–81.29], p = 0.003), skin involvement (OR:
6.33 [1.60–31.55]; p = 0.012), time to presentation (OR
per day: 1.02 [1.002–1.04], p = 0.034) and a low creatin-
ine clearance rate (OR per unit: 0.98 [0.97–0.99]; p =
0.013) were associated with a poor functional outcome.
Discussion
This study of adult patients with SA specifically included
only the 109 cases with native joint infection admitted
to our university hospital. The duration of follow-up en-
abled us to determine the outcomes (including mortality
directly attributable to SA). The frequency of death dir-
ectly attributable to SA (5.6 %) was lower and the poor
functional outcome rate (31.8 %) was higher than ex-
pected. Predictive factors of death directly attributable to
SA were older age, high serum CRP levels, RA and other
inflammatory disease, diabetes mellitus, and confusion
on admission, bacteriema, skin involvement (leg ulcers
and/or eschars) and a low creatinine clearance rate.
Older age, hip joint involvement, skin involvement, a
longer time to presentation and a low creatinine clear-
ance rate were predictive of a poor functional outcome.
In terms of identifying individual cases, complete reli-
ance on retrospective HAI data would have been a prob-
lem. Fortunately, consecutive patients with SA
diagnosed between November 2010 and December 2013
were reported to a prospective diagnosis registry by our
clinicians. Accordingly, 22 patients (20 % of the total)
were identified solely through the diagnosis registry.
Children, adolescents and patients with prosthetic joint
SA were excluded from the study because we considered
that (in comparison with adult patients with native SA)
pathogens, treatments, outcomes, and risk factors for
the development of SA might differ [14, 19–23].
Our results confirmed literature data on the demo-
graphics (age and gender) of patients with SA [12, 24],
the affected joints, the pathogens and the risk factors.
Surprisingly, the most common sites involved were small
joints (31.2 %, which is much higher than the literature
values of below 10 % [5, 6]). This disparity might be re-
lated to our inclusion criteria, since SA as a result of a
skin wound is sometimes excluded from studies in this
field; in the present study, this condition was frequently
observed in patients with small joint involvement. Our
results again emphasize that multiple joint involvement
is not rare [1]. Indeed, 11 of our 109 patients had several
affected joints. The spectrum of causative organisms was
similar to that reported in previous studies, with the
Table 4 Concomitant conditions
Concomitant conditions Number Percent
Heart disease 37 33.9
Current smokers 36 33.0
Diabetes mellitus 26 23.9
Osteoarthritis 24 22.0
Previous cancer 22 20.2
Peripheral arterial disease 19 17.4
Kidney disease 17 13.8
Gout/chondrocalcinosis 15 13.8
Alcohol abuse 13 11.9
Lung disease 12 11.0
Oral corticosteroids 10 9.2
Skin ulceration 10 9.2
Eschars 9 8.2
Liver disease 7 6.4
Rheumatoid arthritis and other
inflammatory rheumatic disease
7 6.4
Intra-articular corticosteroids 3 2.8
Intravenous drug abuse 2 1.8
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Table 5 Univariate analysis of factors possibly associated with mortality attributable directly to septic arthritis
Yes (N = 6) No (N = 101) p-value Odds ratio [95 % CI] Univariate analysis
p-value
Age (years) 82.5 [59–96] 62.0 [16–95] 0.017 1.09 [1.02–1.19] 0.023
Gender (Female) 3 (50 %) 31 (31 %) 0.380 2.26 [0.40–12.80] 0.335
Knee involvement 3 (50 %) 22 (22 %) 0.138 3.59 [0.63–20.61] 0.133
Hip involvement 0 (<1 %) 12 (12 %) 1 not defined 0.993
Multiple joint involvement 2 (33 %) 8 (8 %) 0.097 5.81 [0.73–35.11] 0.062
Cardiovascular disease 3 (50 %) 42 (42 %) 0.694 1.40 [0.25–7.91] 0.686
Skin involvement 4 (67 %) 12 (12 %) 0.004 14.83 [2.62–115.71] 0.003
Rheumatoid arthritis and related conditions 2 (33 %) 5 (5 %) 0.049 9.60 [1.14–64.04] 0.021
Previous cancer 3 (50 %) 19 (19 %) 0.100 4.32 [0.75–24.95] 0.087
Diabetes mellitus 4 (67 %) 22 (22 %) 0.030 7.18 [1.31–54.31] 0.028
Time to presentation (days) 11 [4–24] 7 [0–120] 0.695 0.98 [0.92–1.02] 0.507
Confusion on admission 3 (50 %) 10 (10 %) 0.023 9.10 [1.51–55.39] 0.012
Creatinine clearance (MDRD, ml/min) 32 [23–66] 81 [5–150] 0.003 0.96 [0.92–0.99] 0.009
C-reactive protein (mg/l) 375 [88–640] 120 [3–465] 0.003 1.01 [1.006–1.02] 0.002
Staphylococcus aureus 4 (67 %) 53 (58 %) 1 1.47 [0.27–11] 0.665
Joint surgery 1 (17 %) 57 (56 %) 0.091 0.15 [0.01–1.002] 0.093
Bacteraemia 5 (83 %) 25 (25 %) 0.006 15.20 [2.31–298.70] 0.015
Small joint involvement 0 (<1 %) 32 (32 %) 0.175 not defined 0.993
MDRD Modification of Diet in Renal Disease
Statistically significant results are indicated in bold type
Table 6 Univariate analysis of factors possibly associated with a poor functional outcome in septic arthritis
Yes (N = 28) No (N = 60) p-value Odds ratio [95 % CI] Univariate analysis
p-value
Age (years) 64.0 [36–90] 54.5 [16–95] 0.076 1.02 [1.001–1.05] 0.049
Gender (Female) 10 (36 %) 19 (32 %) 0.707 1.20 [0.46–3.07] 0.707
Knee involvement 3 (11 %) 13 (22 %) 0.252 0.43 [0.09–1.50] 0.224
Hip involvement 8 (29 %) 2 (3 %) 0.001 11.60 [2.65–81.29] 0.003
Multiple joint involvement 3 (11 %) 4 (7 %) 0.675 1.68 [0.31–8.17] 0.517
Small joint involvement 7 (25 %) 23 (38 %) 0.219 0.54 [0.19–1.41] 0.223
Cardiovascular disease 12 (43 %) 19 (32 %) 0.306 1.62 [0.64–4.10] 0.308
Skin involvement 7 (25 %) 3 (5 %) 0.010 6.33 [1.60–31.55] 0.012
Rheumatoid arthritis and related conditions 1 (4 %) 3 (5 %) 1 0.70 [0.03–5.79] 0.765
Previous cancer 8 (29 %) 7 (12 %) 0.049 3.03 [0.97–9.73] 0.056
Diabetes mellitus 7 (25 %) 13 (22 %) 0.728 1.21 [0.40–3.40] 0.728
Time to presentation (days) 15 [0–105] 5 [0–91] 0.016 1.02 [1.002–1.04] 0.034
Creatinine clearance (MDRD, ml/min) 71 [5–130] 94 [29–150] 0.019 0.98 [0.97–0.99] 0.013
C-reactive protein (mg/l) 120 [3–342] 105.5 [3–465] 0.862 0.999 [0.995–1.004] 0.839
Staphylococcus aureus 15 (58 %) 29 (55 %) 0.802 1.13 [0.44–2.96] 0.803
Joint surgery 17 (61 %) 33 (55 %) 0.614 1.26 [0.51–3.21] 0.615
MDRD Modification of Diet in Renal Disease
Statistically significant results are indicated in bold type
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Gram-positive organisms S. aureus and Streptococci be-
ing responsible for 60 % of cases [6]. Septic arthritis due
to MRSA was rare during the present study period (9
cases, accounting for 8.3 % of all episodes) [25]. We
found that a high proportion (35.8 %) of patients with
SA had underlying rheumatic disease, as reported previ-
ously [10, 12]. However, few patients (relative to the lit-
erature data) were affected by RA (n = 4) or other
inflammatory rheumatic diseases (n = 3) [5, 12]. Surpris-
ingly, pre-existing or concomitant cancer was reported
in 22 patients. These conditions are rarely reported on
in this kind of study. Intra-articular corticosteroid injec-
tion and human immunodeficiency virus infection were
also quite rare [7, 10, 11].
Our data strongly suggested that a sample of synovial
fluid should be obtained before antibiotic treatment is
initiated. However, it is also clear that blood cultures
contribute to the diagnosis and should not be omitted.
Cultures of joint aspirate and/or blood were positive in
89 % of cases; this proportion is similar to that observed
in previous studies [6, 26]. The aetiology of SA could
not be determined in only 9 cases (8.2 %). Moreover, the
use of blood culture methods for synovial fluids might
not be of value; further studies are needed to unambigu-
ously resolve this issue.
In the literature, mortality rates range from 4 to 42 %
[15]. This broad range may be due to study-to-study dif-
ference in patient comorbidities, inclusion criteria (chil-
dren, prosthetic joint infections, etc.) and clinical
presentations (since SA can present as an isolated dis-
ease or as part of a sepsis syndrome. Two series pub-
lished between 1997 and 1999 reported mortality rates
of 11.5 and 10 %, respectively [5, 6], and Gupta et al. re-
ported a value of 11 % in 2001 [12]. One series found a
rate of 4 % [24] which is quite similar to our value of
5.6 %. More recently, Munoz-Egea et al. [27] and Lim et
al. [28] reported rates of 7.7 % and 5.5 %, respectively.
Surprisingly, Geirsson et al. found a mortality rate of
1.8 % in a study of 253 cases (69 children and 184
adults) diagnosed in Iceland between 1990 and 2002; an
iatrogenic aetiology was noted in 41.8 % of the adults
[7]. One possible explanation for the low mortality rate
encountered in the present study is our decision to ex-
clude prosthesis infections, since mortality rates for
these patients are usually closer to 20 % [5]. Another
possible explanation relates to the large number of cases
of small-joint infections (fingers and toes), which gener-
ally correspond to limited-scale disease not accompanied
by sepsis syndrome. Indeed, CRP levels were higher in
patients with large joint involvement than in those with
small joint involvement, and an elevated CRP level was a
strong risk factor for deaths directly attributable to SA.
To the best of our knowledge, our results are the first to
highlight CRP in this respect. Although CRP per se was
not tested as a predictive factor in previous studies [5, 6]
an elevated erythrocyte sedimentation rate was predict-
ive of death [12]. We do not have an obvious explan-
ation for the predictive value of skin involvement (leg
ulcers and/or eschars), although Gupta et al. [12] and
Ravindran et al. [24] also found a higher rate of mortal-
ity in patients with leg ulcers. Again, the presence of es-
chars (whether previous or concomitant) had never
previously been tested as predictive factor for death in
SA. However, leg ulcers and above all eschars are found
in the frailest patients; this perhaps explains why these
features are associated with a high mortality rate. We
also confirmed that older age, diabetes mellitus, bacter-
aemia, chronic renal failure, inflammation [29] and con-
fusion [6] on admission are risk factors associated with
death directly attributable to AS.
Furthermore, we observed substantial morbidity; a
poor functional outcome occurred in 32 % of the pa-
tients (in line with the literature data) [5, 6, 24]. In
the present study, older age, hip joint involvement,
longer time to presentation, previous or concomitant
skin involvement and a low creatinine clearance rate
were associated with functional impairment. High
morbidity in patients with SA at the hip joint can be
explained by the frequent need for resection arthro-
plasty. We do not have obvious explanations for the
correlation with skin involvement and a low creatin-
ine clearance rate, although both conditions are asso-
ciated with frailty (which probably prevented adequate
recovery and rehabilitation). Longer time to presenta-
tion was also highlighted as a risk factor in the
present study. This is particularly relevant, and physi-
cians should be aware of this aspect. Moreover, the
suspicion that surgical lavage may be associated with
a poor outcome was not confirmed by our present re-
sults [6, 19].
Our study had several limitations. Firstly, the study
was hospital-based (rather than population-based)
and so its findings cannot be extrapolated to other
populations. Secondly, our study had a relatively
small number of patients. However, SA is a rare
condition, and the implementation of multicentre,
prospective, randomized controlled trials (to ensure
large number of patients) is logistically difficult (al-
beit highly desirable). Thirdly, our study involved an
unusually high proportion of adults with small joint
involvement. However, small joint involvement em-
phasizes the broad spectrum of conditions in SA,
since it can present as an isolated disease or as part
of a sepsis syndrome. Lastly, the study was ambis-
pective (rather than prospective), which prevented us
from obtaining additional data (such as the patients’
functional status on admission, social status and
education level).
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Conclusions
The present study emphasises the continuing poor out-
comes following native SA in adults. Better patient out-
comes will require additional research into the optimal
management of SA (improved diagnosis, joint drainage
methods, antibiotic regimens, treatment duration, etc.).
Key messages
Septic arthritis continues to be associated with a consider-
able degree of morbidity and mortality.
C-reactive protein might a valuable predictive factor
for death directly attributable to SA.
Hip joint involvement is associated with a poor func-
tional outcome.
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